Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced that Founder and CEO Ryan Saadi, MD, MPH, will be attending the J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco, CA.
新泽西州沃伦，2024年12月10日（全球新闻网）-- Tevogen Bio（"Tevogen"或"Tevogen Bio Holdings Inc."）（纳斯达克：TVGN），是一家临床阶段的专业免疫治疗生物技术公司，开发现成的、基因未修改的T细胞疗法，用于治疗传染病和癌症，今天宣布创始人兼首席执行官Ryan Saadi，医学博士，公共卫生硕士，将参加2025年1月13日至16日在加利福尼亚州旧金山举行的摩根大通医疗会议。
The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together key stakeholders to discuss innovations and advancements in the sector.
摩根大通医疗会议是行业中规模最大、信息最丰富的医疗投资研讨会，汇集了关键利益相关者，讨论行业中的创新和进展。
For inquiries about Tevogen Bio's JP Morgan events, please contact Communications at communications@tevogen.com
有关Tevogen Bio的摩根大通活动的咨询，请联系通信部门，邮箱是communications@tevogen.com
About Tevogen Bio
关于Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen是一家临床阶段的专业免疫治疗公司，利用自然界最强大的免疫武器之一，CD8+细胞毒性T淋巴细胞，开发即用型、基因未改造的精准T细胞疗法，以治疗感染性疾病、癌症和神经系统疾病，旨在满足大量患者群体的重大未满足需求。Tevogen的领导层相信，在当前医疗保健时代，可持续性和商业成功依赖于通过先进科学和创新业务模型确保患者的可及性。Tevogen已经在其概念验证临床试验中报告了积极的安全数据，其主要知识产权资产完全归公司所有，不受任何第三方许可协议的限制。这些资产包括三项已授予的专利、九项待审的美国专利和十二项非美国待审专利，其中两项与人工智能有关。
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Tevogen由一支经验丰富的行业领导者和杰出科学家团队驱动，他们在药物开发和全球产品上市方面拥有丰富经验。Tevogen的领导层认为，可及的个性化治疗是医学的下一个前沿，颠覆性的商业模型是维持医疗创新所必需的。
Contacts
联系人
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Tevogen生物通讯-半导体
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
译文内容由第三方软件翻译。
